Belsomra® (suvorexant): Testing for a New Kind of Sleep Drug
NMS Labs offers another unique test to assist physicians with therapeutic drug monitoring (TDM) of patients on
suvorexant (Belsomra®), a sedative hypnotic indicated for the treatment of insomnia. Testing may also be helpful
in detecting abuse of this schedule IV controlled substance.
Suvorexant is the first approved drug in its class, considered a dual orexin receptor antagonist. It blocks binding of
the wake-promoting neuropeptides orexin-A and orexin-B, which are involved in facilitating wakefulness. Along with
the concern for sleep driving and next-day impairment, the usual warnings for hypnotics, such as sedation, poor
coordination and muscle weakness, also apply with suvorexant.